_256_384.jpg)
Drug Approval | April 27, 2026
Cipla wins USFDA nod for first generic of Ventolin HFA strengthening respiratory push
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Collaboration to drive diagnostics exports, tap high-growth regional markets and build scalable commercialization platform
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
FTIR and machine learning-based technology enables real-time, cost-effective quantification of food adulterants
Former Cipla MD & CEO to lead next phase of growth at science-led CDMO platform; Vivek Sharma transitions to advisory role
New minimally invasive biomarker test enables earlier diagnosis and improved clinical decision-making, aligned with global guidelines
The agreements aim to strengthen medicine quality, patient safety and pharmaceutical research in India
Multidisciplinary team expansion brings integrated medical, surgical, and radiation oncology services under one roof
Profitability came under strain. Gross profit fell to EUR 246m, with margins narrowing to 23.7% as negative product mix—particularly in Asia Pacific—weighed on performance
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
Subscribe To Our Newsletter & Stay Updated
